Versant Venture Capital
SelectiveFiled to raiseSan Francisco, CABiotech & pharma, Medical devices, Digital healthLast fund filed October 2022
6 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Versant Voyageurs III | October 2022 | $300M | $300M | 82 |
| Versant Venture Capital IX | October 2022 | $600M | $600M | 82 |
| Versant Vantage III | October 2022 | $299M | $299M | 82 |
| Versant Vantage II | November 2020 | $254M | $254M | 52 |
| Versant Voyageurs II | November 2020 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
11 partners are named across this firm’s filings, 6 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Kirk NielsenNot on the current fund | Selective | Medical devices, Biotech & pharma, Digital health | 18 |
Categories of Versant Venture Capital’s own portfolio companies, based on 78 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Vensana Capital | 19 | Alleviant Medical, Artelon, Ceterix Orthopaedics, CVRx, HOLAIRA, Inari Medical, iVEAcare, Metavention, Monteris Medical US, Moxe Health, NEUWAVE MEDICAL, Okami Medical, Rampart IC, Relievant MedSystems, Respicardia, Sequent Medical, SpyGlass Ophthalmics, VI1, ZYGA TECHNOLOGY |
| U.S Venture Partners | 4 | Inari Medical, Okami Medical, Sequent Medical, ViaLase |
| Vivo Capital | 3 | Aligos Therapeutics, Kanyos Bio, MINERVA SURGICAL |
| $140M |
| $140M |
| 87 |
| Versant Venture Capital VIII | November 2020 | $560M | $560M | 87 |
| Versant Vantage IFiled to raise in 2019, with no closing reported yet. | 2019 | $150M | $0 | 0 |
| Versant Venture Capital VII | September 2018 | $600M | $600M | 74 |
| Versant Voyageurs I | April 2018 | $102M | $102M | 14 |
| Versant Voyageurs I Feeder | April 2018 | $20M | $20M | 1 |
| Versant Venture Capital VI | November 2016 | $400M | $400M | 57 |
| Versant Venture V AIV | November 2016 | $22M | $22M | 32 |
| Versant Venture V AIV Feeder Holdings | November 2016 | $5.3M | $5.3M | 7 |
| Versant Venture Capital V | October 2013 | $300M | $296M | 86 |
| 3 |
| Alex Mayweg | Quiet | Biotech & pharma | 5 | 0 |
| Bradley Bolzon | Quiet | Biotech & pharma | 10 | 0 |
| Carlo Rizzuto | Quiet | Biotech & pharma | 10 | 0 |
| Clare Ozawa | Quiet | Biotech & pharma | 8 | 0 |
| Jerel Davis | Quiet | Biotech & pharma | 13 | 0 |
| Robin PraegerNot on the current fund | Quiet | None listed | 0 | 0 |
| Ross JaffeNot on the current fund | Quiet | Medical devices, Digital health | 5 | 0 |
| Samuel ColellaNot on the current fund | Quiet | Biotech & pharma, Climate & energy, Manufacturing & industrials | 5 | 0 |
| Thomas Woiwode | Quiet | Biotech & pharma | 13 | 0 |
| William LinkNot on the current fund | Quiet | Medical devices, Biotech & pharma, Digital health | 16 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Versant Venture Capital’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Aditum Bio | 2 | Century Therapeutics, Graphite Bio |
| MPM BioVentures | 2 | Aligos Therapeutics, Firefly Bio |
| NaviMed Partners | 2 | AcuFocus, NEOVISTA |
| Polaris Partners | 2 | Jnana Therapeutics, Quentis Therapeutics |
| Samsara Biocapital | 2 | Chinook Therapeutics U.S., Tentarix Biotherapeutics |
| Treo Ventures | 2 | CVRx, iVEAcare |
| Venture Investors Health | 2 | NEUWAVE MEDICAL, ViaLase |
| 270 Healthcare Growth | 1 | Audentes Therapeutics |
| Aisling Capital | 1 | Monte Rosa Therapeutics |
| Arboretum Ventures | 1 | ViaLase |
| ARCH Venture Partners | 1 | Vividion Therapeutics |
| Asset Management Ventures | 1 | Audentes Therapeutics |
A shared board seat: a company where filings name a Versant Venture Capital partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.